SG Americas Securities LLC Raises Stake in Artivion, Inc. $AORT

SG Americas Securities LLC boosted its position in shares of Artivion, Inc. (NYSE:AORT) by 578.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,030 shares of the company’s stock after acquiring an additional 33,277 shares during the period. SG Americas Securities LLC owned about 0.08% of Artivion worth $1,780,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of AORT. Royal Bank of Canada lifted its position in shares of Artivion by 107.0% during the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock worth $952,000 after purchasing an additional 20,010 shares during the last quarter. AQR Capital Management LLC increased its holdings in Artivion by 8.8% in the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after buying an additional 2,823 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Artivion by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after buying an additional 1,032 shares in the last quarter. Creative Planning lifted its holdings in Artivion by 5.6% during the 2nd quarter. Creative Planning now owns 14,272 shares of the company’s stock worth $444,000 after buying an additional 753 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in Artivion by 1.9% during the 2nd quarter. Franklin Resources Inc. now owns 29,263 shares of the company’s stock worth $910,000 after buying an additional 533 shares during the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Stock Performance

Shares of AORT stock opened at $34.14 on Monday. The stock’s 50-day moving average price is $37.71 and its 200 day moving average price is $41.88. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $1.66 billion, a PE ratio of 170.71 and a beta of 1.63. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $48.25.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. The company had revenue of $118.30 million during the quarter, compared to analysts’ expectations of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. Artivion’s revenue for the quarter was up 19.2% on a year-over-year basis. As a group, equities research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Insider Transactions at Artivion

In other news, insider John E. Davis sold 4,573 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total value of $172,767.94. Following the completion of the transaction, the insider owned 230,794 shares in the company, valued at $8,719,397.32. This trade represents a 1.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO James P. Mackin sold 20,962 shares of Artivion stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $37.59, for a total value of $787,961.58. Following the transaction, the chief executive officer directly owned 780,031 shares of the company’s stock, valued at $29,321,365.29. This trade represents a 2.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 133,043 shares of company stock valued at $4,977,158. Company insiders own 7.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Stifel Nicolaus set a $55.00 price objective on Artivion in a report on Thursday, March 5th. Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Canaccord Genuity Group cut their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Finally, Needham & Company LLC restated a “buy” rating and set a $58.00 price objective on shares of Artivion in a research report on Monday, February 2nd. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $50.47.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.